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INTRODUCTION 
Lung cancer is a major health problem worldwide. The incidence is 
increasing globally at a rate of 0.5% per year. It is the leading cause of cancer 
mortality in most of the countries in the world. It remains the most lethal form of 
cancer in men and has now surpassed breast cancer in women as well in USA, 
where 170,000 new cases are diagnosed per year. But in India Lung cancer is 
second only to breast cancer in females. The worldwide incidence is 14% 
whereas it constitutes 6.8% of all carcinomas in India. The increase whether due 
to the actual increase or due to the improvement in diagnostic techniques needs 
to be clarified? Complex circumstances like genetic predisposition, environmental 
exposure, life style habits combine over a lifetime to initiate and promote tumor 
growth in the lung. Despite advances in imaging techniques and treatment 
modalities, the prognosis of lung cancer remains poor, with a five-year survival of 
14% in early stages and less than 5% in locally advanced stages.  Unfortunately 
only 20-30% of patients present with an operable disease, while most of the 
patients present in an advanced stage III and IV. The main reason for late 
presentation in our country is the poor health awareness, delayed recognition 
and the poor referral of patients to the specialized centers 
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AIM OF THE STUDY 
To study the Clinicopathological, Radiological profile, possible associated 
risk factors and diagnostic modalities of Primary Lung Cancer in females. 
 
  
DESIGN OF THE STUDY 
Prospective 
 
 
This study was examined and approved by the Ethical Committee of the 
Institution. 
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REVIEW OF LITERATURE 
Lung cancer is the major cause of cancer-related death in both men and 
women. Emerging evidence indicates that there are differences in the 
pathogenesis and possibly increased susceptibility to lung cancer in women. In 
addition, considerable data support small, but important differences favoring 
women in terms of response to therapy and long-term survival after the diagnosis 
of lung cancer, regardless of histology or stage. These differences in both biology 
and outcome will be important considerations in the design of future trials of 
screening and therapy for lung cancer.  
 
There has been a fourfold increase in lung cancer in women over the past 
30 years and it is estimated that this rise will not plateau until after 2010. This 
increase in lung cancer in women has been referred to as a contemporary 
Epidemic. The rise in lung cancer-related mortality among women   has 
significantly altered the male/female ratio in this disease 
 
While much of this altered epidemiology can be attributed to changing 
patterns of tobacco use, it is becoming increasingly apparent that the relative 
risks (RRs) of specific types of lung cancer, the relationship between smoking 
and lung cancer, as well as the response to therapy may not be the same for 
both sexes. There are several differences between lung cancer in men and 
women that are of growing importance and may impact on diagnosis, treatment, 
and outcome. 
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Sex Differences in Lung Cancer 
Characteristics Sex Differences 
Risk Women may be at greater risk for lung cancer than men 
Molecular variables Different metabolism of tobacco-related carcinogens 
Possible association with HPV infection  
Women have relatively less DRC 
Response to therapy Women have increased response rates to cisplatin-
based chemotherapy compared with men 
Outcome Women have better outcome stage for stage than men 
. 
 
Risk Factors 
Smoking 
Smoking is the overwhelming cause for lung cancer in both men and 
women; 85 to 90% of patients with lung cancer are current or former tobacco 
smokers. Smokers are 22 times more likely to die from lung cancer than 
nonsmokers (41). Although smoking is a risk factor for all histologic types of lung 
cancer, the association is stronger for small cell, squamous cell, and large cell 
carcinoma than for Adeno Carcinoma. Death rate from smoking-related disease 
for men has leveled off, women’s rates continue to rise, both as a delayed effect 
of past smoking and a lower rate of smoking cessation.  
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Environmental Tobacco Smoke 
Environmental tobacco smoke (ETS) accounts for approximately 3,000 
lung cancer deaths each year in the United States among nonsmokers, primarily 
women. A nonsmoking woman has a 24% greater risk of lung cancer if she lives 
with a smoker (41). Urinary levels of nicotine, cotinine, 4-(methylnitrosamino)- 1-
(3-pyridyl)-butanol (NNK), a tobaccospecific carcinogen, and its glucuronide 
(NNALGluc) were elevated in nonsmoking women exposed to ETS compared to 
those who were not exposed. 
 
Indoor Air Pollution 
Domestic cooking is an important duty of an average Indian housewife. On 
an average, an Indian woman spends about four to six hours daily for cooking.  
Mainly four different types of cooking fuels are used in this country. Biomass fuel 
(Wood, Cow-dung cake, agricultural waste, coal etc.), liquefied petroleum gas 
(LPG), kerosene and a mixture of these. About 95% of the rural population in 
India still relies primarily on biomass fuels (dung, crop residues, and wood). Use 
of these fuels causes a number of respiratory problems, which include acute 
respiratory infections in children, chronic obstructive lung disease in non-smokers. 
It has also been implicated as a risk factor for lung cancer in women (12). 
Biomass smoke, however, contains a wide-range of chemicals that are known or 
suspected human carcinogens. Thus, they may be important risk factors for 
development of Lung Cancer. Coal smoke contains many potential carcinogens 
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like SO2, CO, Radon and thoron. Use of Kerosene for cooking has also been 
seen associated with development of Lung Cancer as reported in some studies. 
 
Radiation 
 Exposure to radiation may be from an external source (such as a 
therapeutic X-ray apparatus or a nuclear bomb) or by inhalation of radioactive 
gases. Radioactive gas is related primarily to radon a substance formed during 
the decay of Uranium to stable lead. Occupational exposure to radon and its 
progeny occurs in workers involved in mining Uranium, fluorspar, niobium and 
other substances or in the processing of radioactive materials. 
 
 Patients who have Hodgkin’s disease or breast carcinoma and who have 
been treated with supra diaphragmatic radiation or combined modality therapy 
also may have a slightly increased risk for the development of pulmonary 
carcinoma. 
 
Family History 
Patients with lung cancer have a higher number of relatives with lung 
cancer than control subjects. The simplest explanation of this phenomenon is the 
clustering of cigarette smokers within families. While undoubtedly true, there is 
also an increased risk of lung cancer regardless of family smoking history. This 
finding suggests that genetic and perhaps other shared environmental factors 
may be present in this population.This risk was found to be greater for 
   7
adenocarcinoma of the lung. , the risk was found to be greater in women than in 
men, and again adenocarcinoma was the predominant tissue type. 
 
Occupational Risk for Lung Cancer 
Certain occupations carry a higher risk of lung cancer. The following 
occupational exposures are known to be associated with an increased risk: (a) 
Asbestos: insulation workers and shipyard workers are exposed to asbestos. 
There is some increase in the risk of lung cancer after 10 years of exposure and 
a substantial risk after 20 years of exposure. Concurrent smoking increases the 
risk to 90 fold; (b) Arsenic: smelter workers and vineyard workers are exposed to 
arsenic. The risk is dose related. Lung cancers have an upper lobe 
predominance and there may be multiple primaries; (c) Nickel refinery workers : 
squamous cell carcinoma is more common; (d) Radiation (Uranium mining): oat 
cell carcinoma is more common; (e) Haematite mining: due to radon exposure; (f) 
Hard rock mining; (g) Chromium exposure in ore mining and pigment 
manufacturing: squamous cell variety is most common; (h) Chloromethyl 
exposure in workers in industries: oat cell carcinoma is most common; (i) Ethers 
and mustard gas: squamous and undifferentiated carcinomas are most common; 
(j) Soot, tars exposure in coke oven workers and (k) Oils and coke exposure in 
Gas house workers, roofers and rubber workers. Other occupational exposures 
that are suspected include those to acrylonitrite, berrylium, and dimethyl sulphate. 
No systematic information on occupational risk for lung cancer patients is 
available in India. 
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DIET AND LUNG CANCER 
There is some evidence that certain dietary factors may be protective for 
lung cancer, and others may increase the risk. There are conflicting reports about 
the role of betacarotene and lung cancer, although most reports suggest a 
protective effect. Case control studies from China have shown that vegetable 
intake is a protective factor for lung cancer. Pumpkins and onions had the most 
consistent protective effect. On the other hand, animal food products and dairy 
products have a predisposing effect on lung cancer. Dietary cholesterol and 
animal fat increases the risk of lung cancer. Behera et al (13), however, reported 
that b-carotene and vitamin A levels and vitamin C levels in patients with lung 
cancer compared to healthy controls were not significantly different. 
 
 Patho biology 
         The development of lung cancer is the end result of a complex interplay of 
factors including carcinogen exposure, metabolism, and genetics. Tobacco 
smoke, recognized to be the foremost risk factor for lung cancer, contains more 
than a hundred diverse mutagens and carcinogens, including polycyclic aromatic 
Hydrocarbons, N-nitro amines, and aromatic amines. The initiating activity 
remains for an extended period after the cessation of smoking. 
           Two classes of enzymes play a crucial role in the metabolism of tobacco-
related carcinogens: the phase I and II detoxifying enzymes. While phase I  
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enzymes (ie, cytochrome P450, monooxygenases) activate carcinogens to 
reactive intermediates, their action is balanced by phase II enzymes, which serve 
to convert these same reactive intermediates (ie, reactive oxygen species) to 
inactive conjugates that are more water soluble and hence excreted more readily. 
Polymorphisms have been found to alter the metabolic activity of detoxification 
enzymes. Those active metabolites that are not detoxified bind to DNA forming 
DNA adducts. Women have higher levels of these DNA adducts when compared 
to men.  
Many genetic and epigenetic alterations of tumor suppressor genes have 
been demonstrated in lung cancer. The most frequent genetic alterations found 
are in p53 (in 90 % of small cell lung cancers [SCLCs] 40 to 70% of non-small 
cell lung cancers [NSCLCs]) and in oncogenes such as K-ras. The p53 pathway 
has long been recognized as playing a key role in cell cycle regulation by causing 
arrest in both the G1 and G2 phases in cell division in response to DNA damage. 
This arrest allows for DNA repair or apoptosis. P53 mutation leads to abrogation 
of this arrest and perpetuation of DNA damage and consequent inhibition of the 
normal apoptotic mechanism. Smoking has been found to induce p53 mutation 
via the formation of DNA adducts. Women have been found to have higher levels 
of pulmonary DNA adducts per pack-year than men Of the Ras family of proto-
oncogenes, K-ras is the most frequently affected gene. As in the p53 
genemutation, the formation of DNA adducts secondary to the effects of smoking 
appears to play a pivotal role. Women are three times more likely to carry the K-
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ras mutation than men. In most studies, Ras mutations are predominantly 
associated with adenocarcinoma.  
 
Growth Factor Receptors 
Certain growth factors have been shown to stimulate the growth of both 
normal and neoplastic cells in the lung. A receptor for the autocrine growth factor, 
gastrin releasing peptide receptor (GRPR), has been identified in both small cell 
lung cancer and NSCLC. The GRPR gene is on the X chromosome and escapes 
X-inactivation. It is expressed more frequently in female nonsmokers (than male) 
and is activated earlier in response to tobacco exposure. 
ERBB2 (HER-2/neu) is one of four receptor-type tyrosine kinases that 
form a heterodimer with other members of the ERB-B class and mediates cell 
growth and survival. Previously, several surgical series found that over 
expression of HER-2/neu is associated with a poorer prognosis and survival. 
HER-2/neu is most commonly expressed in Adeno carcinoma, the most common 
subtype in women. 
 
DNA Repair Capacity 
An emerging literature implicates differences in DNA repair capacity (DRC) 
in both the pathogenesis of lung cancer and response to therapy. A complex 
Family of proteins exist to remove damaged DNA segments or to repair 
mismatched nucleotides. Deficiencies in this process are unequivocally 
mutagenic and carcinogenic.  
   11
Paradoxically, this relative deficiency in DRC may relate to the observation 
that women have better responses and survival when treated with platinum 
based chemotherapy.  
 
Hormonal Influences 
The most obvious biological differences between the male and female are 
hormonal. An estrogen driven environment is a recognized factor in the 
Pathogenesis of breast, endometrial, and ovarian cancers. With the increasing 
rates of lung cancer in women and their increased susceptibility to the 
detrimental effects of tobacco smoke compared to men, the role of female steroid 
sex hormones has been hypothesized to be a factor in lung carcinogenesis. 
Estrogen receptors are abundantly expressed in normal lung tissue and in lung 
tumor cell lines at the messenger RNA level. Estradiol has a proliferative effect 
on normal lung fibroblasts and lung cancer cell lines in vitro. There was a 17-fold 
increase in cellular proliferation in lung cancer-derived cell line as opposed to 
only a 3.8-fold increase when normal lung fibroblasts were incubated with _-
estradiol. This finding suggests an increased responsiveness of malignant clones 
to estrogen. The exact role of estrogens in lung cancer is not clear, but they may 
act as direct carcinogens via the formation of DNA adducts.  early menopause 
was associated with a decreased risk of Adeno carcinoma in women. Soy 
phytoestrogens have been shown to compete with endogenous estradiol for ERs 
and have been shown to have a protective effect against lung cancer. 
Premenopausal women tended to present with more extensive disease and 
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Adeno carcinoma than postmenopausal women. Favorable prognostic factors: 
low-stage disease, surgical therapy, age _ 50 years, and female sex. 
 
 
1999 WHO Histological Classification of Lung Tumors 
 
A. Squamous cell carcinoma (epidermoid carcinoma) 
     Variant:  
· Papillary 
· Clear cell 
· Small cell 
· Basaloid 
 
B. Small-cell carcinoma 
     Variant: 
· Combined Small cell carcinoma  
 
C. Adenocarcinoma 
       · Acinar   
· Papillary  
· Bronchio-alveolar carcinoma 
· Solid carcinoma with mucin 
· Adenocarcinoma with mixed sub types 
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      Variants: 
· Well differentiated fetal Adenocarcinoma 
· Mucinous (Colloid) Adenocarcinoma 
· Mucinous cystadenocarcinoma 
· Signet-ring Adenocarcinoma 
· Clear cell adenocarcinoma 
 
D. Large-cell carcinoma      
     Variants: 
· Large Cell neuroendocrine Carcinoma 
· Basaloid Carcinoma 
· Lymphoepithelioma like Carcinoma 
· Clear cell Carcinoma 
· Large cell Carcinoma  with rhabdoid phenotype 
 
E. Adeno Squamous carcinoma  
 
F. Carcinomas with pleomorphic, sarcomatoid or sarcomatous elements 
· Carcinomas with spindle and/or giant Cells 
· Pleomorphic Carcinoma 
· Spindle Cell Carcinoma 
· Giant Cell Carcinoma 
· Carcinosarcoma 
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· Blastoma (pulmonary blastoma) 
· Others. 
 
G. Carcinoid Tumor  
· Typical Carcinoid  
· Atypical Carcinoid 
 
H. Carcinomas of Salivary Gland type  
· Adenoid cystic carcinoma 
· Mucoepidermoid carcinoma  
 
I. Unclassified Carcinoma 
 The selection of therapy is becoming more specifically related to tumor 
histology. The histopathologic  appearance of lung carcinoma remains an 
important guide to prognosis and treatment. 
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Clinical Manifestations 
 
Lung Cancer presents with diverse clinical manifestations. Clinical 
features may be due to the following reasons. 
 
Clinical features due to primary tumor 
 Centrally located tumors produce different symptoms than do peripherally 
located tumors. 
 
Clinical features due to central tumors 
Cough 
 It is the commonest symptom and occurs in 75 % or more of patients. 
Cough may be produced by a small tumor acting as a foreign body interfering 
with bronchial peristalsis or by neoplastic erosion of bronchial mucosa. 
 
Hemoptysis 
 It occurs in 5 to 51 % of patients. It is usually scanty and is due to 
ulceration of bronchial mucosa. 
 
Chest pain 
 It is vague, persistent and poorly localized. It is due to peribronchial and 
perivascular nerve involvement. 
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Dyspnoea 
 It occurs in approximately 58 % of patients. It may be due to emphysema, 
pleural effusion, atelectasis, bronchopulomonary infection, phrenic nerve 
paralysis and O2 transport defect in bronchioloalveolar carcinoma. 
 
Wheeze 
 It occurs in 2 % cases. It is due to fixed mechanical obstruction below the 
carina & it is not changed after cough. 
 
Stridor 
 It is due to narrowing of trachea and main bronchi at about the level of 
carina. 
 
Fever and sepsis 
 It is due to post obstructive pneumonia. 
 
Clinical features due to peripheral tumors 
Pleuritic Chest Pain 
 It is either due to involvement of the parietal pleura or due to pleurisy 
arising as a result of post obstructive segmental or subsegmental pneumonia. 
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Dyspnoea 
 It is restrictive in nature. It is either due to pleural effusion or due to 
pleuritic chest pain. 
 
Cough 
 It is less common except in brochioloalveolar carcinoma. 
 
Clinical features due to intrathoracic spread 
Neurological complications 
 Due to involvement of 8th cervical and 1st thoracic nerve the patient will 
present with characteristic pain in the shoulder and in the arm along the 
distribution of ulnar nerve. Sensory loss with weakness and wasting of small 
muscles of the hand will occur. Patient may present with horner syndrome due to 
involvement of cervical sympathetic nerve. Involvement of recurrent laryngeal 
nerve produces hoarseness of voice & dysphagia (common on the left side). 
Diaphragmatic palsy due to phrenic nerve damage is a possibility. Erosion of the 
ribs (commonly 1st and 2nd) may occur. 
 
S.V.C Obstruction 
 It is obstructed either by primary tumors or by metastatic lymph nodes. It 
was first described by William Hunter in 1757. Obstruction may be above or 
below the azygos vein. The most common presenting symptoms are oedema of 
the head, neck, arms and breast, dyspnoea, cough and orthopnoea. The oedema 
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is pitting and varies with changes in position. Collateral veins fill from above 
downwards. Its incidence ranges from 4 to 19 %. 
 
Pleural and pericardial effusion 
 Pleural effusion is commonly due to direct involvement of pleura by tumor. 
It may be due to lymphatic obstruction or disruption of thoracic duct (chylothorax). 
Features of cardiac tamponade, sinus tachycardia or atrial fibrillation may appear 
due to involvement of pericardium or heart. 
 
Dysphagia 
 It may occur due to compression of oesophagus by posterior mediastinal 
node. Immediate cough upon swallowing may occur due to broncho-pleural 
fistula. 
 Pulmonary artery constriction or pulmonary artery stenosis (extrinsic) may 
occur due to tumor involvement. 
 
Clinical features due to extrathoracic metastasis 
Extrathoracic metastasis is common in small cell carcinoma. It may involve any 
organ or tissue, but lymphnode, bone, brain, liver, adrenals and skin are 
commonly involved. Bone and Brain involvement usually produces symptoms 
and others are usually silent. 
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Central Nervous system 
 Metastasis may involve the brain, meninges and spinal cord. Spinal cord 
involvement produces back pain which is localized and progressive in nature. 
Other symptoms are numbness, tingling, weakness of an extremity, bladder and 
bowel disturbance and unsteadiness of gait. Due to intracranial involvement 
patient may present with headache, vomiting, altered mental status, weakness, 
seizures, cranial nerve abnormality, hemiparesis and cerebellar ataxia. 
 
Lymph node metastasis 
 Lymphatic spread is more common in small cell carcinoma. The whole of 
right lung and lower lobe of left lung ultimately drains in to right supraclavicular 
node via hilar and paratracheal nodes. Upper lobe of left lung drains in to the 
para aortic, hilar and carinal nodes. Enlarged node is usually painful and hard in 
consistency. 
 
Bone metastasis 
 It produces distressing and unremitting pain which may be due to 
pathological fracture or bone erosion. 
 
Hepatic metastasis 
 Enlarged palpable liver and jaundice are unusual. Hard and irregular liver 
suggest hepatic metastasis. 
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Skin metastasis 
 It may occur occasionally. 
 
Paraneoplastic Syndrome 
Paraneoplastic syndromes are non-metastatic metabolic or neuromuscular 
complications of lung cancer. It occurs most commonly in small cell carcinoma. 
Ectopic hormones are produced from the neurosecretory granules within the 
malignant cells. 
a. Metabolic Disorders 
Hypercalcemia 
 It is caused by ectopic parathormone secretion by tumor cells. It 
commonly occurs in squamous cell carcinoma. It is seen in about 10 % of cancer 
patients. Patients present with thirst, polyurea nocturia, nausea, vomiting, 
anorexia, abdominal pain, mental confusion, hypotonia, stupor and ultimately 
coma. 
 
Syndrome of inappropriate antiduresis 
 It is commonest of the syndromes of tumor hormonogenesis (2-22 %) and 
common in small cell carcinoma. Patients present with headache, drowsiness, 
mental confusion, disorientation, convulsion, coma, hypothermia and death. 
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Clinical syndrome due to excess ACTH 
 It is fairly uncommong (< 2 %) and is widely variable in severity. Patients 
present with dependent oedema, pigmentation, weakness and wasting of 
muscles particularly of limb girdle. Hypertension and hyperglycemia may be 
present. Cushing’s syndrome is unusual. 
 
Clinical syndrome due to other hormones 
 Oxytocin, GHRH, somatostatin, neurophysin, liptrophin, prolactin, 
calcitonin gastrin, glucagons etc may be produced by tumor cells. Very rarely 
these hormones produce symptoms. 
 
b. Neurologic and Neuromascular disorders 
Peripheral neuropathy  
 Commonly seen in small cell carcinoma. It may be motor, sensory or 
mixed and may be accompanied by muscle wasting or weakness. 
 
Autonomic neuropathy 
 It may produce postural hypotension and disturbance of intestinal motility. 
Cerebellar ataxia with nystagmus, impaired co-ordination and dysarthria may 
occur. 
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Polymyositis/dermatomyositis syndrome 
 It is characterized by proximal muscle weakness, pain and tenderness and 
a characteristic facial heliotrope rash. 
Myasthenic syndrome 
 Patients present with muscle weakness and in contrast to myasthenia 
gravis it improves with repeated effort. Other differentiating points are muscular 
wasting, loss of tendon reflex and infrequency of bulbar involvement. 
 
Hypertrophic Pulmonary Osteoarthropathy 
 It was first described by Bomberger (1889) and Marie (1890). Thompson 
(1904) first described its associated with lung cancer. Its incidence varies from 2 
to 48 %. Patients present with bone pain in the involved areas which are often 
hot and tender to touch. There may be associated pain and swelling of wrists, 
ankles and knee joints. Clubbing occurs in 90 % of cases. It is commonly 
associated with adenocarcinoma. 
 
Gynaecosmastia 
 It may occur occasionally. The histological types most frequently found are 
large cell and adenocarcinoma.   
 
Dermatologic 
 Pigmentation, pruritus, lanugohirsuitism, acanthosis nigricans and 
erythema gyratum nigricans. 
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Vascular 
 Thrombophlebitis migrans, arterial thrombosis and non bacterial 
thrombotic endocarditis. 
 
Hematologic 
 Anemia, hemolytic anemia, red cell aplasia, thrombocytopenic purpura, 
intravascular coagulopathy, hypofibrinogenemia and cosinophilia. 
 
Immunologic 
 Dermatomyositis, systemic sclerosis, membranous glomerulo nephritis 
and rickets. 
 
General systemic 
 Pyrexia, anorexia, cachexia and taste dysfunction.   
 
Investigations 
After a complete history and physical examination, imaging is the main 
first-line investigation: 
• Chest X-ray is an important initial screen as it can reveal the following: the 
size and extent of any tumor, local spread, complications such as 
lymphadenopathy or pleural effusion, secondary lobar collapse, and hilar 
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or mediastinal lymph node enlargement. However, a 'normal' chest X-ray 
does not exclude primary lung malignancy 
• Should be done in anteroposterior and lateral views using a high voltage 
(>125kV) to ensure adequate penetration through the tumor and the 
mediastinum 
• Review of a prior X-ray is essential, if possible. The lesion may have been 
present for several years, and not changed in size, making the diagnosis 
less likely to be malignant 
• If chest X-ray is 'normal' but suspicion for lung cancer exists, then a 
computed tomography (CT) scan should be done. (Note that chest X-ray 
is not considered adequate screening for a lung primary) 
 
Blood tests should routinely be ordered as part of the work-up to evaluate 
the patient's overall fitness: 
• Complete blood count (CBC) may reveal anemia or leukocytosis if there is 
secondary infection. Thrombocytosis or thrombocytopenia may be part of 
a paraneoplastic syndrome 
• Liver function tests (LFTs) may be abnormal if there are metastases to the 
liver 
• Renal function test should routinely be ordered as part of the work-up to 
evaluate the patient's overall fitness, and will influence the patient's ability 
to tolerate certain chemotherapeutic regimens 
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• Calcium group tests may reveal hypercalcemia secondary to either bone 
metastasis or a paraneoplastic process 
• Cytology of sputum may reveal cancer cells; these are diagnostic if found, 
although negative cytology does not rule out primary lung malignancies 
A specialist normally performs the following scans and biopsies: 
• CT scan is necessary to evaluate primary disease and spread of 
suspected tumors locally and distantly and to assess lymph node 
involvement. CT is recommended as a staging procedure for patients with 
either non-small cell or small cell carcinoma 
• Magnetic resonance imaging (MRI) has no advantage over CT scanning 
for evaluation of enlarged lymph nodes. MRI is not useful in routine 
staging, but can help to clarify the extent of tumor invasion in the 
mediastinum, root of neck, chest wall, and diaphragm if CT scanning 
results are equivocal 
• Positron emission tomography (PET): accurate imaging investigation for 
possible intrathoracic lymph node involvement. It is best used in 
conjunction with CT scanning for accurate localization and interpretation. 
PET/CT is quickly gaining acceptance as the most informative test for 
ruling out more advanced disease in potentially resectable candidates.  
A negative PET and CT exam of the mediastinum may, at times, abrogate 
the need for surgical mediastinoscopic evaluation 
   26
• Enhanced MRI scans of the brain and isotope bone scans may detect 
asymptomatic occult metastases in many patients; therefore, brain 
imaging is mandatory for any patient being considered for surgical 
resection 
• When CT scanning the thorax it seems sensible to include views of the 
liver and adrenal glands 
• Biopsy by CT-guided needle, bronchoscopy, mediastinoscopy, or 
thoracoscopy: histologic confirmation of any suspicion of primary lung 
malignancies is essential to accurately diagnose the malignancy, ascertain 
its cell type and to plan the relevant treatment and predict the prognosis. 
Bronchoscopy is usually performed by a pulmonologist or thoracic 
surgeon, although some primary care physicians, especially in isolated 
areas, may offer this investigation. Transbronchial needle aspiration can 
be used to sample a parenchymal mass, mediastinal masses, or 
paratracheal lymph nodes 
• Percutaneous needle biopsy: needle biopsy of a peripheral suspicious 
lesion, often under CT scanning guidance. It is useful for patients who are 
unfit for surgery. It has a high diagnostic success rate, but a negative 
biopsy should not necessarily exclude cancer 
• Mediastinoscopy or mediastinotomy: an invasive procedure allowing 
endoscopic or direct views of the mediastinum. It is useful in evaluating 
the true extent of a mediastinal lymph node involvement. At the discretion 
of the surgeon, it might be omitted in a surgical candidate if there is no 
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evidence of mediastinal lymph node involvement by both PET and CT 
scanning, particularly if the tumor is peripheral, although a proportion of 
patients may have microscopic lymph node metastases 
• Thoracoscopy and thoracentesis: an invasive endoscopic procedure 
allowing views of the pleura and pleural spaces, and aspiration of any 
pleural space fluid. It is useful in differentiating malignant pleural effusions 
from those secondary to consolidation distal to an obstruction lesion 
• Biopsy of lymph nodes or pleura: surgical resection of axillary or cervical 
lymph nodes, or of the pleura, or percutaneous biopsies of them, may be 
needed in cases of diagnostic doubt or to assess local spread 
• Cytology of sputum, bronchial washings, or pleural space fluid: cancer 
cells are diagnostic if found; but as this exam is highly insensitive, a 
negative cytology does not rule out primary lung malignancies 
  
Staging 
Staging is the process of finding out if cancer is localized or widespread.  
It will show if the cancer has spread to other body structures and, if so, how far. 
The treatment and prognosis (outlook for survival) for a patient with lung cancer 
depends, to a large extent, on the cancer's stage. 
 
Staging of Small Cell Lung Cancer  
For small cell lung cancers, a two-stage system is most often used. These 
are "limited stage" and "extensive stage". Limited stage usually means that the 
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cancer is only in one lung and in lymph nodes on the same side of the chest. 
Spread of the cancer to the other lung, to lymph nodes on the other side of the 
chest, or to distant organs indicates extensive disease. Many doctors consider 
small cell lung cancer that has spread to the fluid around the lung to be an 
extensive stage. 
Small cell lung cancer is staged in this way because it helps separate 
tumors that can be treated more effectively with radiation therapy from those 
which cannot. About two-thirds of the people with small cell lung cancer will have 
extensive disease when their cancer is first found. 
 
Staging of Non-Small Cell Lung Cancer (NSCLC) 
The system most often used to describe the growth and spread of non-small cell 
lung cancer (NSCLC) is the TNM staging system, also known as the American 
Joint Committee on Cancer (AJCC) system. T stands for tumor (its size and how 
far it has spread within the lung and to nearby organs), N stands for spread to 
lymph nodes and M is for metastasis (spread to distant organs). In TNM staging, 
information about the tumor, lymph nodes, and metastasis is combined and a 
stage is assigned to specific TNM groupings. The grouped stages are described 
using Roman numerals from 0 to IV. 
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MATERIALS AND METHODS 
 
An open prospective study of female patients who attended Thoracic 
Medicine Department of Government General Hospital Chennai and Institute of 
Thoracic Medicine, Chetpet with Clinical and Radiological features suspicious of 
Primary Lung Cancer were studied over a period of 15 months between June 
2006 and August 2007. 
 
The study protocol included a detailed history regarding the onset and 
progress of the disease, lifetime exposure to smoking, detailed occupational 
history, residence and exposure to indoor air pollution due to burning of organic 
fuels. A detailed history regarding malignancy in the first degree relatives of 
patients was also taken. Female patients with a clinical assessment suggestive 
of primary lung cancer and proven histology only were included in this study. 
Total numbers of female Patients diagnosed to have Primary lung cancer were 
compared with the total numbers of male Patients with Primary Lung cancer 
diagnosed during the same period to detect the Sex ratio. 
 
The complaints which were evaluated in detail included Cough, Sputum, 
hemoptysis, chest pain, dyspnoea, fever, weight loss, hoarseness of voice, 
dysphagia and symptoms suggestive of SVC obstruction, para neoplastic 
syndromes and systemic metastasis. A detailed general and systemic 
examination was performed. 
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 All patients were subjected to baseline blood investigations, sputum for 
AFB smear and culture, sputum for non tuberculous culture, sputum for cytology, 
chest X-ray PA view and corresponding lateral view, ultrasound chest and 
abdomen. Computerized Tomography of the chest and upper abdomen was 
done to characterize the lesion further, to help to arrive at tissue diagnosis and to 
stage the disease. FOB was performed in all patients who were fit for the 
procedure. Computerized Tomography of brain and bone scan was done if 
indicated. 
 
 Following investigations helped in the histopathological confirmation of the 
diagnosis. 
1. Computerized Tomography guided needle biopsy. 
2. Ultrasound guided needle biopsy. 
3. Endobronchial biopsy with fiber optic bronchoscopy. 
4. Exision biopsy of accessible peripheral Lymph node. 
 
Fiber optic bronchoscopy was performed with the single channel 
bronchoscope (Pentax, Japan). Under local anesthesia, 2 ml of 2 % lignocaine 
was injected transtracheally after test dose along with spraying of 4% lignocaine 
using hand atomizer just prior to the procedure. Lignocaine jelly was applied to 
the effective length of fiber optic bronchoscope. The fiber optic bronchoscope 
was passed transnasally/transorally in the supine position. The normal side was 
visualized first and then the suspected abnormal side. Biopsy was performed in 
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patients with obvious endo bronchial lesion. Mucosal brushings and washings 
were obtained from the area surrounding the abnormal segments on radiological 
basis in case of patients without endo bronchial lesion. A central tumor was 
defined as a tumor that was evident with in the bronchial tree at fiber optic 
bronchoscope and a peripheral tumor as one that was not visualized at 
bronchoscopy. X-ray wise, central tumor was defined as tumor arising at (or) 
close to the hilum, peripheral tumor as tumor arising beyond the hilum. Post 
broncoscopic sputum was sent for cytological examination. Patients were 
subjected to FNAC / Exision biopsy of peripheral Lymph node.. 
 
Computerized Tomography / Ultrasound guided needle biopsy was done 
in patients when indicated. The biopsy was done using Atovac Gun core biopsy 
needle. The needle size was 18G, 10 cm to 15 cm in length with 1 cm markings. 
The distal tip was ultrasound sensitive. The needle also has a over sheath 
cannula for Computerized Tomography guidance. The needle length was 
adjusted using pins. With computerized Tomography, Ultrasound guidance the 
lesion was localized, under cover of local anesthesia the needle length was 
adjusted according to the lesion and core biopsy obtained which was 2 cm to  
2.5 cm bit. 
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The specimens obtained were: 
Computerized Tomography guided needle biopsy 
Fiber optic bronchoscope Brushing/Washing and biopsy 
Ultrasound guided needle biopsy 
 
Smears for cytology were fixed in isopropyl alcohol for 30 minutes and 
stained with Hematoxylin and eosin stain. Smears were air dried and fixed in 
methanol for 30 minutes. Air dried smears were fixed with MGG(Maygrunwald 
Giemsa) stain, slides were mounted and reported under microscope by cyto 
pathologist. 
 
Biopsy specimens were fixed in formaldehyde (10%) for 24 hours. These 
slides were stained with Hematoxylin and eosin and reported by pathologist. 
Pleural fluid was centrifuged and smears stained in Hematoxylin and eosin. 
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RESULTS 
31 patients were included in the study. Pathological diagnosis was 
possible in 30 patients. Cell type diagnosis was not possible in one patient. 
However clinical and X-ray features suggestive of Primary Lung cancer and that 
was confirmed by presence of Malignant cells in pleural fluid and 
ultrasonography guided needle biopsy specimen. 
Age:  
In this study the age range was from 28 to 68 years.  
Age Incidence of Primary Lung Cancer in this Study 
Age Incidence of Primary Lung Cancer
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Maximum number of patients presented between 41 to 50 years of age. 
 
Sex Ratio: 
 Total number of patients diagnosed to have Primary Lung Carcinoma 
during the period of study was 163(Male: 132 and Female: 31). Female  
(F: M ratio was 1:4.3) contribution was 19 % of the total. 
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Histo Pathological Types: 
 Out of 31 cases included in this study, 22 patients were Adeno Carcinoma, 
6 patients were Squamous cell Carcinoma, 1 patient each for Small cell 
Carcinoma and Anaplastic Carcinoma. 
Histo Pathological Types in this Study 
Cell type No of Patients Percentage 
Adeno Carcinoma 
Squamous cell Carcinoma 
Small cell Carcinoma 
Ana plastic Carcinoma 
Cell type not possible 
22 
6 
1 
1 
1 
70.96 
19.35 
3.23 
3.23 
3.23 
Total 31 100.00 
 
HistoPathological Types
22
72%
6
19%
1
3%
1
3%
1
3%
Adeno Carcinoma Squamous cell Carcinoma Small cell Carcinoma
Anaplastic Carcinoma Cell type not possible
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Risk Factors: 
Smoking:  
 No Patient in this study was an active smoker. But exposure to ETS 
(Environmental tobacco smoke) was present in 14 patients (45.16 %). Out of 14 
patients 9 patients (40.91 %) were Adeno Carcinoma, 3 patients (50 %) were 
Squamous Cell Carcinoma, ETS exposure was present in 1 patient each for 
Small cell and Anaplastic Carcinoma. 
 
Indoor air pollution: 
 12 patients (38.71 %) gave definite History of exposure to biomass fuels 
like Cow dung cake and agricultural waste, wood and coal. Of these 12 patients, 
10 (45.45 %) were Adeno Carcinoma. 
 
Occupation: 
 Out of 31 patients, 1 patient (3.23 %) gave history of exposure to asbestos 
in the working place. 
 
Radiation: 
 2 patients (6.45 %) gave history of exposure to radiation.  Both were 
Adeno Carcinoma (9.09 %). 
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Genetic Factors: 
 Genetic predisposition for Malignancy was present in 5 patients (16.13 %) 
in this study. Out of which 4 patients (18.18 %) were Adeno Carcinoma. Out of 4 
patients 2 patients gave history of previous Malignancy like Hodgkin’s lymphoma 
and Carcinoma cervix (Squamous cell). Other 2 patients (9.09 %) had family 
history of Malignancy in breast and Lung. 
Possible Risk Factors identified in this study 
R I S K     F A C T O R S 
ENVIRONMENT 
ETS Bio-Mass 
Fuels 
Occupation Radiation 
GENETIC 
 
CELL TYPE 
No. % No. % No. % No. % No. % 
Adeno 
Carcinoma 
9 40.91 10 45.45 1 4.55 2 9.09 4 18.18
Squamous 
Cell 
Carcinoma 
3 50 1 16.67 0 0 0 0 1 16.67
Small Cell 
Carcinoma 
1 100 0 0 0 0 0 0 0 0 
Ana plastic 
Carcinoma 
1 100 1 100 0 0 0 0 0 0 
Total 
 
14 45.16 12 38.71 1 3.23 2 6.45 5 16.13
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Risk Factors identified in the study
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• One patient whose cell type not possible included. 
• No Patient in this study gave history of Exposure to Environmental Industrial 
pollutants. 
• Prior history of ATT present in only one case C.No 24 
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Clinical Features: 
 The most common pulmonary symptoms were breathlessness, cough, 
chest pain and hemoptysis. Of this breathlessness was present in 16 patients 
(51.61 %), cough was present in 13 patients (41.94 %) followed by chest pain in 
13 patients (41.94 %) and hemoptysis in 10 patients (32.26 %). 
Salient Features of different Cell Types 
C E L L   T Y P E 
Adeno Squamous Small 
cell 
Anaplastic Total 
 
SYMPTOM 
No % No % No % No % No % 
Cough 8 36.36 4 66.67 1 100 0 0 13 41.94
Chest Pain 11 50 1 16.67 0 0 1 100 13 41.94
Hemoptysis 4 18.18 5 83.33 1 100 0 0 10 32.26
Breathlessness 11 50 3 50 1 100 1 100 16 51.61
 
• One patient whose cell type diagnosis was not possible had cough and 
breathlessness. 
• Out of 3 patients with Bronchioloalveolar subtype of Adeno Carcinoma,  
2 patients presented with bronchorrhea. 
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SVC obstruction was present in 2 patients (6.45 %) and the cell type was 
squamous cell Carcinoma (i.e. SVC obstruction was present in 33.33 % of 
patients with squamous cell carcinoma). CNS metastasis was seen in 3 patients 
(9.68 %), of which 1 patient was small cell carcinoma (100 %), 1 patient was 
squamous cell carcinoma (16.67 %) and 1 patient was adeno carcinoma  
(4.55 %). Liver metastasis was seen in 1 patient (3.23 %) that was adeno 
carcinoma (4.55 %). Bone (Ribs & Vertebral) metastasis was seen in 3 patients 
(9.68 %) of which 2 patients were adeno carcinoma (9.09 %) and 1 patient was 
anaplastic carcinoma (100 %). Hoarseness of voice was present in 4 patients 
(12.90 %) and actual vocal cord palsy was seen in 3 patients. 
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Chest X-ray Features: 
 The most common presentation was mass lesion 54.84 % (n=17) followed 
by pleural effusion 35.48 % (n=11). 
Radiologic Manifestations of different Cell Types 
C E L L   T Y P E 
Adeno Squamous Small 
cell 
Anaplastic Total 
 
FINDINGS 
No % No % No % No % No % 
*  Lt Side 10 45.45 4 66.67 0 0 0 0 14 45.16
Rt Side 8 36.36 2 33.33 1 100 0 0 11 35.48
Bi lateral 4 18.18 0 0 0 0 1 100 5 16.13
Pulmonary mass 15 68.18 1 16.67 0 0 1 100 17 54.84
Hilar mass 3 13.64 4 66.67 1 100 0 0 8 25.81
Mediastinal mass 1 4.55 0 0 0 0 0 0 1 3.23 
Cavity 0 0 1 16.67 0 0 0 0 1 3.23 
Consolidation 2 9.09 0 0 0 0 0 0 2 6.45 
Collapse 2 9.09 3 50 1 100 0 0 6 19.35
#Pleural Effusion 8 36.36 2 33.33 1 100 0 0 11 35.48
Coin Shadow 0 0 0 0 0 0 0 0 0 0 
Rib/Vertebral 
erosion 
2 9.09 0 0 0 0 0 0 2 6.45 
Diaphragm Palsy 1 4.55 0 0 0 0 0 0 1 3.23 
*    1 patient who was not typed had Lt Side involvement 
#    1 patient not typed 
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Fig. 1 - Chest Skiagram PA view – showing mass (Left) upper zone. 
 
 
 
 
 
 
 
 
 
 
Fig. 2 – Computerized Tomography scan – showing mass (Left)  
upper lobe posterior segment of the above patient. 
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Fig.3 Chest Skiagram PA view – showing (left) hilar prominence 
 
 
 
 
 
 
 
 
 
 
Fig.4 Computerized Tomography scan – showing (left) hilar mass lesion of 
the above patient 
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Diagnostic Modalities: 
 Computerized Tomography scan was done in all 31 patients. 
Computerized Tomography helped in histo pathological diagnosis by way of 
computerized Tomography guided needle biopsy of suspected mass in 12 
patients (38.71 %). Bronchus cut off sign was positive in 3 patients. 
Computerized Tomography diagnosed 4 patients with mediastinal nodes, 2 
patients with rib/vertebral metastasis and 2 patients with nodules in the lung 
which were not seen on the chest X-ray. 
 
 Fiber optic bronchoscope was done in 26 patients (83.87 %). Bronchial 
brushing cytology yield was 26.92 %(n=7). Endobronchial biopsy yield was 
15.38% (n=4). 
 
 Ultrasonography of the chest was useful in identifying peripheral tumors 
close to the chest wall. It helped in the histo pathological diagnosis by the way of 
guided needle biopsy of suspected mass in 8 patients (25.81 %).  
 
 Supra clavicular Node FNAC/Biopsy yielded positive results in 6 patients 
(19.35 %). 
 
 
 
 
   45
Primary diagnostic modalities for Histopathological documentation 
Methods 
CT FOB USG 
Cell Type Total 
Number 
of Cases NO % NO % No % 
Adeno 22 10 45.45 5 22.73 7 31.82 
Squamous 6 1 16.67 5 83.33 0 0 
Small Cell 1 0 0 1 100 0 0 
Anaplastic 1 1 100 0 0 0 0 
Not typed 1 0 0 0 0 1 100 
Total 31 12 38.71 11 35.48 8 25.81 
 
Staging: 
 Staging was done based on clinical, radiographic and bronchoscopic 
findings. Patients in whom bronchoscopy was not done due to poor performance 
status, staging was done by means of other two methods. 
 
 Non small cell carcinoma patients were staged based on TNM 
classification whereas small cell carcinoma patient was staged in a simple 
fashion in to two categories like limited disease and extensive disease. 
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Fig.5 Chest Skiagram PA view – showing (left) hilar mass lesion with 
elevation of (left) hemidiaphragm 
 
 
 
 
 
 
 
 
Lung cancer histology. 
  Adenocarcinoma-characterized by 
heterogeneous differentiation in the same 
tumor. 
 Lung cancer histology 
Squamous cell-characterized by the 
presence of cytokeratin differentiation with 
keratinization and intercellular bridges. 
   
 
Fig. 6 
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TNM Staging of Non small cell lung cancer in this study 
Stage I Stage II Stage III Stage IV Cell Type 
A B A B A B  
Adeno - - - 1 3 10 8 
Squamous - 1 - - - 3 2 
Anaplastic - - - - - - 1 
Not possible - - - - - - 1 
Total - 1 - 1 3 13 12 
Percentage 0 3.33 0 3.33 10 43.33 40 
TNM Staging of Non Small Cell Cancer
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• 1 patient who was not typed included 
• 1 patient with small cell carcinoma had extensive disease 
• Most of the patients were in stage III B (43.33 %) and IV (40 %) at the time 
of presentation (n=25). 
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DISCUSSION 
Lung Cancer is one of the commonest malignant neoplasm in India both in 
males and females, and the Gender difference is narrowing. Complex 
circumstances like genetic predisposition, environmental exposure, life style 
habits combine over a lifetime to initiate and promote tumor growth in the lung. 
 
In this prospective study of 31 patients, 30 patients had confirmed 
pathological diagnosis, but in 1 patient malignant cell could be identified but cell 
type was not possible. 
 
The age range was from 28 to 68 years. Maximum number of patients in 
this study was between 41 and 50 years. Mean age was 49 years. This is less 
than the study conducted by Jindal SK and Behera D 1990(5) where the mean 
age was 52 years. 
 
The female contribution to Primary lung malignancy was 19% in this study. 
In the previous study conducted in our institution by Rajashekaran et al in 1993, 
the female contribution was 3% (27). In another study conducted during 2000 in 
our institution, the female contribution was 14%. This shows a definite trend 
towards increasing incidence in females. 
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The most common histopathological type in this study was Adeno 
Carcinoma (70.96 %). The second most common type was Squamous cell 
Carcinoma (19.35 %). This is in corroboration with the study done by 
T.Behera,T.Balamugesh 2005 (12). 
 
Tobacco smoking is the most important risk factor for lung cancer. None of 
the patients in this study was a smoker. But exposure to Environmental tobacco 
smoke was present in 45 % of patients. 
 
Environmental tobacco smoke (ETS) is an important indoor as well as 
outdoor air pollutant that may be a contributing risk factor. Exposure to 
environmental tobacco smoke was present in 14 patients (45.16 %). This is less 
compared to the study done by T.Behera , T. Balamugesh, 2005 (12), where the 
exposure was 53 %. Adeno and Squamous cell carcinoma were almost equally 
distributed in patients exposed to ETS in this study. ETS exposure was present 
in one patient with small cell carcinoma. 
 
Significant exposure to domestic biomass cooking fuels like wood, 
cowdung cake, agricultural waste, coal etc was present in 12 patients (38.71 %). 
This is less compared to the study done by T.Behera, T.Balamurugesh, 2005 
(12). Among 12 patients 10 were Adeno Carcinoma. 
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Exposure to occupational carcinogens like asbestos was present in  
1 patient (3.23 %) and the cell type was Adeno Carcinoma. In the study 
conducted by DC Vos Irvine and colleagues, the incidence was 5.7 % (8).  
 
Exposure to Radiation was present in 2 patients (6.45 %). Of these  
2 patients, one patient gave history of Radiotherapy treatment for Hodgkin's 
Lymphoma 15 years back and another patient is residing in area of atomic power 
station for more than 25 years. Genetic Predisposition to get cancer was present 
in 5 patients (16.13 %). 
 
Most common pulmonary symptom in this study was breathlessness  
16 patients (51.61 %) followed by Cough 13 patients (41.94 %) and chest pain 13 
patients (41.94 %). Cough and Hemoptysis were present predominantly in 
patients with Squamous cell carcinoma. Increased breathlessness in this study 
could be attributed to the Later stage of the disease in most of the patients and to 
the pleural involvement. 
 
The most common radiological presentation was mass lesion, which was 
seen in 17 patients (54.84 %) followed by pleural effusion in 11 patients (35.48 
%). Adeno Carcinoma present as a peripheral mass is 68 % and as a central 
lesion in 13 % of patients. Squamous cell carcinoma present as a peripheral 
mass in 16 % and as a central lesion in 66 % of patients. 1 patient of small cell 
carcinoma was present as a central lesion (100 %). This is in corroboration with 
   51
the study done by D.Behera, T.Balamugesh 2004 (45). 2 Patients with 
bronchiloalveolar sub type of Adeno Carcinoma presented as consolidation in  
X-ray. 
 
Post bronchoscopic sputum cytology was positive in 2 patients (6.45 %) 
and the most common tumor associated was squamous cell carcinoma. 
 
Computerized Tomography study was done in all 31 patients. 
Computerized Tomography guided needle biopsy of suspected mass was done 
in 14 patients. Positive results were obtained in 12 patients (85.71 %).  
 
USG guided needle biopsy of suspected mass lesion was positive in all 
patients who underwent the procedure (100 %). CT/USG guided needle biopsy 
helped in the diagnosis of 20 patients (65 %) out of 31 patients. Whereas in the 
study conducted by C R PAYNE et al (46), the yield was much higher (88 %).  
 
Fibre optic bronchoscopy was done in 26 patients (83.87 %). It helped in 
diagnosis by the way of endo bronchial Biopsy in 4 patients (15.38 %) and by 
bronchial brushing cytology in 7 patients (26.92 %).This is in corroboration with 
the study conducted by Gupta PK et al Rajasthan, in 1993 (50) where the 
combined yield of bronchial biopsy and brush cytology was 45 %.  
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Supraclavicular Lymph node FNAC/biopsy yielded positive results in 6 
patients (19.35 %) whereas in the study conducted by Jindal SK and Behera D 
(5), the yield was 10.7 %. 
 
In this study majority of the patients (83.33 %) were in the advanced 
stages of the disease (IIIB and IV) at the time of presentation. In the study 
conducted by Rajendra Prasad et al 2004 (49), 74.2 % of patients were in the 
advanced stage. In the study conducted by Rajashekaran et al 1993 (27), 96 % 
were in the advanced stage of the disease. 
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CONCLUSIONS 
 
• There is definitely a increasing trend in the incidence of Primary 
Lung Cancer in females when compared with the previous studies 
conducted in our institution. This disturbing trend inline with global 
situation needs further evaluation. 
• Maximum number of patients was between 41-50 years of age. 
• Environmental Tobacco Smoke and Bio-mass cooking fuel 
exposure constituted about 84 % of Risk Factors identified in this 
study. 
• In addition to the above risk factors, occupational pollutants / 
Radiation have an additive effect in the background of Genetic 
predisposition in the causation of Lung Cancer in females. 
• Most common Pathological cell type in females was Adeno 
Carcinoma. 
• Most common Radiological presentation was Mass lesion followed 
by pleural effusion. 
• 83 % of patients were in the advanced stage of disease at the time 
of presentation. 
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• Fibreoptic bronchoscope Biopsy and Brushing / Computerized 
Tomography / Ultrasound guided core needle Biopsy were valuable 
tools to get a tissue diagnosis. 
• Lung lesions in females in high risk age group of 40 years and 
above should be investigated without gender bias thoroughly to rule 
out malignancy. This approach may result in diagnosing 
malignancy at an early stage. Primary Lung malignancies are 
common only in smokers, is proved as a misconception as 
evidenced by this study.   
 
 
   
 
Short Comings of this Study 
• The number of cases studied was only 31. 
• Bronchoscopy not done in 5 patients due to poor performance status. 
• 3 patients didn’t reveal any risk factors. 
• Exact quantification of exposure to risk factors not possible. 
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ABBREVIATION 
 
 
DRC  - DNA Repair Capacity 
ETS  - Environmental Tobacco Smoke 
NSCLC - Non Small Cell Lung Cancer 
SCLC  - Small Cell Lung Cancer 
ACTH  - Adreno Corticotropic Hormone 
 GHRH - Growth Hormone Releasing Hormone 
 SVC  - Superior Venacava 
 FOB  - Fibreoptic Bronchoscope 
 FNAC  - Fine Needle Aspiration Cytology 
 ATT  - Anti Tuberculous Treatment 
 CNS   - Central Nervous System 
 
   
 
MASTER CHART 
 
 
S.No Age 
(Years) 
Cell 
Type 
Risk 
Factors
Pulmonary 
Symptoms
Chest 
X-ray 
Diagnostic 
Mode 
Staging
1 65 2 1 1,2,3,4 2,5,9 3 7 
2 60 2 5 3,4 1,9 3 6 
3 40 1 1 3,4 2,5,8,9 3 7 
4 51 1 4,5 2,4 2,4 1 6 
5 51 1 2 2,4 2,5,9 2 6 
6 50 1 2 4 1,4 1 4 
7 37 1 1,3 0 1,13 1 7 
8 50 3 1 1,3,4 2,5,8,9 3 9 
9 60 2 1 1,4 1,4,5,8 3 6 
10 42 1 1 0 1,4,11 1 6 
11 55 1 5 2,4 1,4,8,12 1 5 
12 65 1 1 1,2 1,4,5 1 6 
13 47 1 2 1 2,7 1 5 
14 65 1 5 3 3,4 1 7 
15 45 0 0 1,4 1,9 2 7 
16 40 1 2 1 2,4 2 6 
17 50 1 1 2 1,4,9 1 6 
18 50 4 1,2 2,4 3,4 1 7 
19 41 1 1,2 1,3,4 3,4 2 7 
20 45 1 2 2 1,4,9 2 7 
21 40 1 4 2,4 1,4 3 6 
22 55 1 1,2 1,4 2,9 3 6 
23 45 2 0 1,3 1,5,8 3 7 
24 32 1 2 1,2,4 3,4 2 7 
25 28 2 0 3 2,6 3 2 
26 68 1 1 1,2,3 1,4,9 3 6 
27 39 1 5 2 1,4 3 7 
28 45 1 1 4 2,9 1 6 
29 49 1 2 1 2,7 2 5 
30 57 1 2 2,4 3,4,11 2 7 
31 63 2 1,2 1,3 1,5,8 1 6 
   
 
KEY TO MASTER CHART 
 
 
Cell type 
 
Not possible                 0 
Adeno Carcinoma        1 
Squamous Cell CA       2 
Small Cell Carcinoma   3 
Anaplastic Carcinoma   4 
 
 
Risk Factors 
 
No Risk Factors        0 
ETS                          1 
Bio Mass Fuels         2 
Occupation               3 
Radiation                  4 
Genetic                     5 
Active Smoking         6 
 
 
Pulmonary Symptoms 
 
Nil                         0 
Cough                   1 
Chest Pain            2 
Hemoptysis           3 
Breathlessness     4 
 
Chest X-ray 
 
Lt Side                          1 
Rt Side                         2 
Bilateral                        3 
Pulmonary Mass          4 
Hilar Mass                    5 
Cavity                           6 
Consolidation               7 
Collapse                       8 
Pleural Effusion            9 
Coin Shadow              10 
Rib/Vertebral Erosion  11 
Diaphragm Palsy        12 
Mediastinal Mass        13 
 
 
Diagnostic mode 
 
CT guided Biopsy      1 
USG guided Biopsy   2 
Fiber optic 
     Bronchoscope      3 
 
Staging 
 
NSCLC 
IA                            1 
IB                            2 
IIA                           3 
IIB                           4 
IIIA                          5 
IIIB                          6 
IV                            7 
 
SCLC      
Limited Disease      8 
Extensive Disease  9 
 
                
 
